Patent US4734279A successfully refreshed from Google Patents.
US4734279A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Combination of immunoglobulins with therapeutic agents
Assignee: Biotest Pharma GmbH
•
Filing: 1985-07-19
•
Granted: 1988-03-29
•
Expires: 2005-07-19
Abstract
Abstract A compositon for treating diseases which comprises a therapeutically effective amount of an antibacterial, antiviral, or antimycotic agent, antitrypsin, antithrombin, interferon, or lysozyme, and an immunoenhancing amount of immunoglobulins IgG, IgM, and IgA, and a method of therapy of a mammal in need thereof are disclosed.
Inventors
- 👤 Wolfgang Stephan
- 👤 Herbert Dichtelmuller
- 👤 Alexander Thrun
- 👤 Hans Schleussner
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 02:08
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/395; A61P; A61P31/00; A61P31/04; A61P31/10; A61P31/12; Y; Y10; Y10S; Y10S424/00; Y10S424/804; Y10S424/806; Y10S435/00; Y10S435/8215; Y10S435/911
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
41 words
A pharmaceutical composition comprising a therapeutically effective amount of (a) a therapeutic agent, wherein the agent is an antibacterial agent, tuftsin, antitrypsin, antithrombin, interferon, fibronectin, or lysozyme, and (b) an immunoenhancing amount of a mixture of immunoglobulins IgG, IgM, and IgA.
Claim 2
Dependent Claim
41 words
A pharmaceutical composition comprising a therapeutically effective amount of (a) a therapeutic agent, wherein the agent is an antibacterial agent, tuftsin, antitrypsin, antithrombin, interferon, fibronectin, or lysozyme, and (b) an immunoenhancing amount of a mixture of immunoglobulins IgG, IgM, and IgA.
Claim 3
Dependent Claim
13 words
The composition of claim 1, wherein the therapeutic agent is an antibacterial agent.
Claim 4
Dependent Claim
11 words
The composition of claim 1, wherein the therapeutic agent is tuftsin.
Claim 5
Dependent Claim
11 words
The composition of claim 1, wherein the therapeutic agent is fibronectin.
Claim 6
Dependent Claim
14 words
The composition of claim 1, wherein the therapeutic agent is α, β, or τ-interferon.
Claim 7
Dependent Claim
11 words
The composition of claim 1, wherein the therapeutic agent is α-antitrypsin.
Claim 8
Dependent Claim
12 words
The composition of claim 1, wherein the therapeutic agent is antithrombin III.
Claim 9
Dependent Claim
11 words
The composition of claim 1, wherein the therapeutic agent is lysozyme.
Claim 10
Dependent Claim
13 words
The composition of claim 2, wherein the antibacterial agent is a cephalosporin antibiotic.
Claim 11
Dependent Claim
11 words
The composition of claim 2, wherein the antibacterial agent is moxalactam.
Claim 12
Dependent Claim
52 words
A synergistic method of therapy of a mammal in need thereof which comprises administration of (a) a therapeutically effective agglutinizing amounts of immunoglobulins IgG, IgM, and IgA and (b) a therapeutically effective amount of a second therapeutic agent of the class consisting of antibacterial agents, tuftsin antitrypsin, antithrombin, fibronectin, interferon or lysozyme.
Claim 13
Dependent Claim
52 words
A synergistic method of therapy of a mammal in need thereof which comprises administration of (a) a therapeutically effective agglutinizing amounts of immunoglobulins IgG, IgM, and IgA and (b) a therapeutically effective amount of a second therapeutic agent of the class consisting of antibacterial agents, tuftsin antitrypsin, antithrombin, fibronectin, interferon or lysozyme.
Claim 14
Dependent Claim
15 words
The method of claim 11, wherein the antibacterial agent is a cephalosporin antibiotic or moxalactam.
Claim 15
Dependent Claim
20 words
A method of claim 12 in which the immunoglobulin mixture and the second therapeutic agent are administered in a mixture.
Claim 16
Dependent Claim
21 words
A method of claim 12 in which the immunoglobulin mixture and the second therapeutic agent are administered in separate dosage units.
Claim 17
Dependent Claim
12 words
A method of claim 11 wherein the second therapeutic agent is tuftsin.
Claim 18
Dependent Claim
12 words
A method of claim 11 wherein the second therapeutic agent is fibronectin.
Claim 19
Dependent Claim
15 words
A method of claim 11 wherein the second therapeutic agent is α, β, or γ-interferon.
Claim 20
Dependent Claim
14 words
A method of claim 11 wherein the second therapeutic agent is α 1 -antitrypsin.
Claim 21
Dependent Claim
13 words
A method of claim 11 wherein the second therapeutic agent is antithrombin III.
Claim 22
Dependent Claim
12 words
A method of claim 11 wherein the second therapeutic agent is lysozyme.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-03-29 | 1991-09-28 | 1992-03-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-03-29 | 1995-09-28 | 1996-03-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-03-29 | 1999-09-28 | 2000-03-29 | $7700.00 | Window Closed / Lapsed |